Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Assets (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Current Assets data on record, last reported at $66.9 million in Q3 2025.

  • For Q3 2025, Current Assets rose 55.97% year-over-year to $66.9 million; the TTM value through Sep 2025 reached $66.9 million, up 55.97%, while the annual FY2024 figure was $54.4 million, 94.62% up from the prior year.
  • Current Assets reached $66.9 million in Q3 2025 per CRVS's latest filing, down from $75.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $75.8 million in Q2 2025 and bottomed at $22.9 million in Q1 2024.
  • Average Current Assets over 4 years is $47.3 million, with a median of $45.5 million recorded in 2025.
  • Peak YoY movement for Current Assets: tumbled 44.77% in 2023, then surged 99.08% in 2025.
  • A 4-year view of Current Assets shows it stood at $43.7 million in 2022, then tumbled by 35.97% to $28.0 million in 2023, then soared by 94.62% to $54.4 million in 2024, then grew by 23.04% to $66.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $66.9 million in Q3 2025, $75.8 million in Q2 2025, and $45.5 million in Q1 2025.